https://www.thersagroup.com/ https://www.thersagroup.com/news-views https://www.thersagroup.com/contact https://www.thersagroup.com/interim-fractional https://www.thersagroup.com/about https://www.thersagroup.com/executive-search https://www.thersagroup.com/sectors https://www.thersagroup.com/all-articles https://www.thersagroup.com/case-studies https://www.thersagroup.com/sectors/biotech https://www.thersagroup.com/sectors/speciality-pharma https://www.thersagroup.com/sectors/cdmo-pharma https://www.thersagroup.com/sectors/pe-ve-backed https://www.thersagroup.com/sectors/digital-health https://www.thersagroup.com/sectors/diagnostics https://www.thersagroup.com/case-studies/targimmune-interim-clinical-operations-leader https://www.thersagroup.com/case-studies/sixfold-biosciences-interim-fractional-cfo https://www.thersagroup.com/case-studies/proveca-chief-medical-officer https://www.thersagroup.com/case-studies/prescient-chief-executive-officer https://www.thersagroup.com/case-studies/norgine-interim-cfo https://www.thersagroup.com/case-studies/lundbeck-interim-epidemiologist https://www.thersagroup.com/case-studies/ligand-vp-transactions https://www.thersagroup.com/case-studies/lift-biosciences-chief-executive-officer https://www.thersagroup.com/case-studies/hemotune-president-of-the-board https://www.thersagroup.com/case-studies/alentis-interim-senior-clinical-scientist https://www.thersagroup.com/case-studies/atai-life-sciences-chief-operating-officer https://www.thersagroup.com/case-studies/baseimmune-interim-chief-business-officer https://www.thersagroup.com/all-articles/universal-mrna-influenza-vaccines-moving-into-phase-3-registration-trials https://www.thersagroup.com/all-articles/ai-in-patient-stratification-optimising-clinical-trial-enrolment https://www.thersagroup.com/all-articles/kras-g12c-inhibitors-progressing-daraxonrasib-in-pancreatic-cancer https://www.thersagroup.com/all-articles/companion-diagnostics-de-risking-clinical-trial-design https://www.thersagroup.com/all-articles/oral-glp-1-therapeutics-the-next-frontier-in-obesity-care https://www.thersagroup.com/all-articles/next-generation-tuberculosis-diagnostics-global-deployment-strategies https://www.thersagroup.com/all-articles/exosome-based-drug-delivery-platforms-clinical-trial-milestones https://www.thersagroup.com/all-articles/inside-the-global-race-to-build-faster-smarter-and-safer-technologies https://www.thersagroup.com/all-articles/de-risking-biotech-valuations-the-resurgence-of-public-markets https://www.thersagroup.com/all-articles/rna-editing-therapies-adar-mediated-platforms-enter-the-clinic https://www.thersagroup.com/all-articles/n-of-1-customised-therapeutics-scalable-regulatory-architectures https://www.thersagroup.com/all-articles/commercialising-rezdiffra-the-launch-of-the-first-approved-mash-therapy https://www.thersagroup.com/all-articles/decentralised-testing-sourcing-the-leadership-to-scale-home-based-diagnostics https://www.thersagroup.com/all-articles/onshoring-active-pharmaceutical-ingredients-(apis)-to-western-europe https://www.thersagroup.com/all-articles/targeted-protein-degraders-advancing-protacs-into-solid-tumour-trials https://www.thersagroup.com/all-articles/how-streaming-platforms-are-reshaping-the-entertainment-industry https://www.thersagroup.com/all-articles/synthetic-control-arms-harnessing-real-world-evidence-(rwe) https://www.thersagroup.com/all-articles/the-fda--priority-review-voucher-accelerating-orphan-drug-time-to-market https://www.thersagroup.com/all-articles/next-generation-crispr-gene-editing-base-and-prime-editing-in-the-clinic https://www.thersagroup.com/all-articles/targeted-alpha-therapies-navigating-the-radiopharmaceutical-boom https://www.thersagroup.com/all-articles/ai-in-drug-discovery-moving-computational-molecules-into-phase-2 https://www.thersagroup.com/all-articles/how-minimalist-living-is-influencing-modern-design-and-habits https://www.thersagroup.com/all-articles/harmonising-regulatory-frameworks-across-the-eu https://www.thersagroup.com/all-articles/commercialisation-pathways-for-amyloid-targeting-alzheimer-s-therapies https://www.thersagroup.com/all-articles/multi-cancer-early-detection-mced-blood-tests-nhs-trial-milestones https://www.thersagroup.com/all-articles/car-t-cell-therapy-expansion-in-autoimmune-disease https://www.thersagroup.com/legal/terms-conditions https://www.thersagroup.com/legal/privacy-policy